Non-adherence to prescribed therapy can create extraordinary risks for patients. Even when provided with correct diagnoses and effective treatment plans, patients can often fail to take their medication as directed for a variety of reasons—including cost, confusion, regimen complexity, language barriers, misperceptions of disease severity, or lack of usable information about their condition and the therapy. And because a wide range of potentially poor health outcomes is associated with patient non-adherence, the real cost for providers and patients may be unquantifiable—wasted time, wasted resources and unchecked disease progression possibly leading to mortality.
Pharma brand teams are committed to helping patients get the full benefits of their therapy and invest substantial resources in helping patients stay adherent, but even then, patients may still struggle. For some brands, patients may share common obstacles to adherence, such as specific side effects, cost challenges or poorly controlled disease symptoms. In these situations, pharma often makes specific resources or programs available; however, providers and patients may not be aware of these tools when they are most needed.
But what if your team could help HCPs predict which of their patients are at risk for non-adherence and direct them to the right support?
Using AI + RWD to Overcome Common Challenges
Imagine if AI could monitor real-world data like lab values, see that blood sugar is not well controlled, and trigger an indication to a patient’s HCP that they may not be compliant with their current diabetes medication. Or picture a patient taking a regular cardiovascular medication, but who is fast approaching the Medicare “donut hole” where their costs are likely to jump significantly. We’re close to making this a reality.
A precision engagement approach gives pharma brand teams the power to overcome all these adherence hazards and helps HCPs handle each of these potential scenarios with preemptive and specific responses or guidance. By predicting patients likely to have difficulty staying on their treatment regimen, brand teams can educate physicians on the distinct challenges these patients face and provide the right support to the right patients before they need it. As a result, more patients who are likely to struggle with adherence can be identified and helped―before outcomes are affected.
Free Planning Tool
To help you get started with using AI and RWD to identify patients likely to be non-adherent, OptimizeRx has created a free guide with a step-by-step approach to planning an AI / RWD strategy. You’ll be guided to determine the information HCPs should know about when and why patients fail to take their medication as directed, what actions they should take, what characteristics define these patients, and more. Download our guide to help you create repeatable and actionable strategies for overcoming patient non-adherence. This essential framework can become the foundation of your AI / RWD program.